Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Last month, the European Commission granted orphan medicinal product designation to the company's product candidate ARCT-032 for the treatment of cystic fibrosis (CF). The designation is likely to support the development of ARCT-032, including certain protocol assistance, access to the centralized authorization procedure, exemption from fees and research funding, along with 10 years of market exclusivity upon potential approval. Earlier in November 2023, the FDA granted an Orphan Drug designation to ARCT-032 for the treatment of CF. This could be the reason for the stock to remain high during the said time frame. Image Source: Zacks Investment Research Per the company, the first CF patient in its early-stage study of ARCT-032 has successfully completed two administrations of the investigational drug candidate. Arcturus remains on track to share interim data from the phase Ib study in the first half of 2024. ARCT-032 is developed using the company's proprietary Lunar lipid-m
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284% return over the last five years [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024Business Wire
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
- Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
ARCT
Earnings
- 3/7/24 - Beat
ARCT
Sec Filings
- 4/29/24 - Form DEF
- 4/5/24 - Form 8-K
- 4/5/24 - Form SC
- ARCT's page on the SEC website